Each year diabetes researchers from all over the world gather for the annual meeting of the European Association for the Study of Diabetes (EASD). Many of the latest advances that will be discussed at the 54^th annual meeting, which starts October 1 in Berlin, include research JDRF has funded to advance new breakthroughs and therapies for people with type 1 diabetes (T1D).

As one of the largest international annual conference on diabetes research, more than 45 studies will be presented by scientists who are or were JDRF funded.

Here are highlights of JDRF-funded research that will be featured at the conference:

• On Tuesday, October 2, Rohit Kulkarni, M.D., Ph.D., of the Joslin Diabetes Center will be receiving the Renold Prize which honors excellent islet researchers.
• On Wednesday, October 3, ‑EASD and JDRF will hold a session called “Looking into the future: developing new interventions for T1D.” Carla Greenbaum, M.D., from the Benaroya Research Institute in Seattle, will give an update on prevention trials, and University of Miami researcher Jay S. Skyler, M.D., M.A.C.P., will talk about hope and hype with new interventions to discuss “Where are we with type 1 diabetes?”
• On Thursday, October 4, Bruce Perkins, M.D., M.P.H., of the Lunenfeld-Tanenbaum Research Institute in Toronto and Joslin Diabetes Center’s Lori Laffel, M.D., M.P.H., will discuss whether the drug empagliflozin, which has been approved for treatment of type 2 diabetes, should be used to supplement insulin in the treatment of T1D.
• Later on Thursday, Kumar Sharma, M.D., from the University of Texas San Antonio will present a study that looked at the connection between diabetes and chronic kidney disease, specifically the impact of metabolic abnormalities.
• And finally, on Friday, October 5, Colin Dayan, M.D., Ph.D., from Cardiff University in the United Kingdom, will talk about his recent study with an immune therapy.

To see where JDRF actively supports T1D research around the world, click here.